17.92
price down icon8.94%   -1.76
after-market アフターアワーズ: 17.92
loading

Travere Therapeutics Inc (TVTX) 最新ニュース

pulisher
04:30 AM

Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025 - Bluefield Daily Telegraph

04:30 AM
pulisher
Mar 26, 2025

Is Travere Therapeutics, Inc. (NASDAQ:TVTX) the Best Small Cap Stock to Buy Before They Explode? - Insider Monkey

Mar 26, 2025
pulisher
Mar 26, 2025

10 Best Small-Cap Stocks to Buy Before They Explode - Insider Monkey

Mar 26, 2025
pulisher
Mar 26, 2025

Nephrologists Embrace Earlier, More Aggressive IgAN Treatment as Branded Therapies from Calliditas, Travere, and Novartis Continue to Gain Traction, According to Spherix Global Insights - Yahoo Finance

Mar 26, 2025
pulisher
Mar 23, 2025

When (TVTX) Moves Investors should Listen - news.stocktradersdaily.com

Mar 23, 2025
pulisher
Mar 18, 2025

Travere seeks FDA approval for potential FSGS treatment By Investing.com - Investing.com Australia

Mar 18, 2025
pulisher
Mar 17, 2025

Travere rises on co's marketing application for kidney disease drug - TradingView

Mar 17, 2025
pulisher
Mar 17, 2025

Travere seeks FDA approval for potential FSGS treatment - Investing.com India

Mar 17, 2025
pulisher
Mar 17, 2025

Travere Therapeutics Submits sNDA To FDA For Approval Of Filspari (Sparsentan) For The Treatment Of FSGS - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS - The Manila Times

Mar 17, 2025
pulisher
Mar 17, 2025

Travere Therapeutics Submits sNDA for FILSPARI as Potential First FDA-Approved Treatment for FSGS - Nasdaq

Mar 17, 2025
pulisher
Mar 17, 2025

Breakthrough: First-Ever FSGS Treatment Could Get FDA Green LightFILSPARI Shows Superior Results - StockTitan

Mar 17, 2025
pulisher
Mar 14, 2025

High Growth Tech Stocks In The US With Promising Potential - Simply Wall St

Mar 14, 2025
pulisher
Mar 13, 2025

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Mar 13, 2025
pulisher
Mar 12, 2025

US Bancorp DE Has $554,000 Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

Travere Therapeutics Expands Team with 77,200 Shares in Strategic Equity Grants - Stock Titan

Mar 12, 2025
pulisher
Mar 11, 2025

Focal Segmental Glomerulosclerosis Treatment Market Size - openPR

Mar 11, 2025
pulisher
Mar 11, 2025

Is Eli Lilly Stock a Buy? - The Globe and Mail

Mar 11, 2025
pulisher
Mar 09, 2025

Why Travere Therapeutics Inc. (TVTX) Went Up On Tuesday? - MSN

Mar 09, 2025
pulisher
Mar 08, 2025

What To Expect From Travere Therapeutics Inc (TVTX) Q4 2024 Earnings - GuruFocus.com

Mar 08, 2025
pulisher
Mar 07, 2025

Travere Therapeutics: Tricky Outlook Gives Me Pause For ThoughtDowngrade - Seeking Alpha

Mar 07, 2025
pulisher
Mar 02, 2025

When the Price of (TVTX) Talks, People Listen - Stock Traders Daily

Mar 02, 2025
pulisher
Mar 01, 2025

Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $44.00 - Defense World

Mar 01, 2025
pulisher
Feb 28, 2025

JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Travere Therapeutics (NASDAQ:TVTX) Stock - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

20,749 Shares in Travere Therapeutics, Inc. (NASDAQ:TVTX) Purchased by Ieq Capital LLC - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $35.00 at Citigroup - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Wedbush Lowers Earnings Estimates for Travere Therapeutics - Defense World

Feb 28, 2025
pulisher
Feb 27, 2025

Can Ligand's Triple FDA Wins Offset Its $31M Q4 Loss? Revenue Jumps 52% - StockTitan

Feb 27, 2025
pulisher
Feb 27, 2025

Q1 EPS Estimate for Travere Therapeutics Lowered by Analyst - MarketBeat

Feb 27, 2025
pulisher
Feb 27, 2025

Impax Asset Management Group plc Purchases New Stake in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat

Feb 27, 2025
pulisher
Feb 27, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 26, 2025

Mirum Pharmaceuticals, Inc. SEC 10-K Report - TradingView

Feb 26, 2025
pulisher
Feb 25, 2025

Travere Therapeutics' (TVTX) Overweight Rating Reaffirmed at Cantor Fitzgerald - MarketBeat

Feb 25, 2025
pulisher
Feb 24, 2025

Analyst Expectations For Travere Therapeutics's Future - Benzinga

Feb 24, 2025
pulisher
Feb 24, 2025

Travere Therapeutics to Participate at Upcoming Investor Conferences - The Manila Times

Feb 24, 2025
pulisher
Feb 24, 2025

Citi raises Travere Therapeutics price target to $35, maintains buy By Investing.com - Investing.com Canada

Feb 24, 2025
pulisher
Feb 24, 2025

Citi raises Travere Therapeutics price target to $35, maintains buy - Investing.com India

Feb 24, 2025
pulisher
Feb 23, 2025

Travere Therapeutics Skyrockets After Reaching FDA Deal For Kidney Disease Drug - MSN

Feb 23, 2025
pulisher
Feb 23, 2025

Travere Therapeutics, Inc. (TVTX): the Best Performing Pharma Stock So Far in 2025 - Insider Monkey

Feb 23, 2025
pulisher
Feb 22, 2025

Travere Therapeutics price target raised to $30 from $24 at TD Cowen - Yahoo Finance

Feb 22, 2025
pulisher
Feb 22, 2025

Travere Therapeutics, Inc. (NASDAQ:TVTX) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 22, 2025
pulisher
Feb 22, 2025

Travere Therapeutics Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance

Feb 22, 2025
pulisher
Feb 21, 2025

Travere Therapeutics’ Earnings Call Reveals Growth and Challenges - TipRanks

Feb 21, 2025
pulisher
Feb 21, 2025

US FDA approves Mirum Pharma's genetic disorder drug -February 21, 2025 at 12:07 pm EST - Marketscreener.com

Feb 21, 2025
pulisher
Feb 21, 2025

Travere Therapeutics, Inc. SEC 10-K Report - TradingView

Feb 21, 2025
pulisher
Feb 21, 2025

Travere therapeutics chief medical officer sells $60k in stock - MSN

Feb 21, 2025
pulisher
Feb 21, 2025

Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times

Feb 21, 2025
pulisher
Feb 21, 2025

Travere Therapeutics Inc (TVTX) Q4 2024 Earnings Call Highlights: Strong Phil Spari Sales and ... - Yahoo Finance

Feb 21, 2025
pulisher
Feb 21, 2025

Travere Therapeutics Inc (TVTX) Q4 2024 Earnings Call Highlights: Strong Phil Spari Sales and ... By GuruFocus - Investing.com Canada

Feb 21, 2025
pulisher
Feb 20, 2025

Travere Therapeutics Posts Strong 2024 Financial Results - TipRanks

Feb 20, 2025
pulisher
Feb 20, 2025

Earnings call transcript: Travere Therapeutics Q4 2024 sees earnings beat but stock drops - Investing.com

Feb 20, 2025
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
大文字化:     |  ボリューム (24 時間):